Evidence map›Paper›PMID 38926266›Full record

Trial reportAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

Effect of Activated Charcoal on Mavacamten Pharmacokinetics in Healthy Participants.

Samira Merali, Manting Chiang, Caroline Sychterz, Longfei Chao, Tara Simmons, Yiru Xu, Alice Zhao, Massimo Attanasio, Bindu Murthy, Vidya Perera

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05320094 (An Open-label Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Pharmacokinetics of Mavacamten in Healthy Participants), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05320094 phase1completednot on this map

An Open-label Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Pharmacokinetics of Mavacamten in Healthy Participants

TypeinterventionalSponsorBristol-Myers SquibbRan2022 to 2022Enrolled45ConditionsHealthy ParticipantsArmsMavacamten, Activated Charcoal with Sorbitol
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Samira MeraliBristol Myers Squibb, Princeton, NJ, USA. samira.merali@bms.com.ORCID http://orcid.org/0000-0001-6659-3687
Manting ChiangBristol Myers Squibb, Princeton, NJ, USA.
Caroline SychterzBristol Myers Squibb, Princeton, NJ, USA.
Longfei ChaoBristol Myers Squibb, Princeton, NJ, USA.
Tara SimmonsBristol Myers Squibb, Princeton, NJ, USA.
Yiru XuBristol Myers Squibb, Princeton, NJ, USA.
Alice ZhaoCytel Inc., Cambridge, MA, USA.
Massimo AttanasioBristol Myers Squibb, Princeton, NJ, USA.
Bindu MurthyBristol Myers Squibb, Princeton, NJ, USA.
Vidya PereraBristol Myers Squibb, Princeton, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the effect of activated charcoal on the single-dose pharmacokinetics of mavacamten when administered 2 h or 6 h after mavacamten dosing.

methodsIn this open-label, randomized, parallel-group study, healthy adults were randomized into three groups to receive mavacamten 15 mg alone or mavacamten 15 mg plus activated charcoal 50 g administered either 2 h or 6 h after mavacamten dosing. Pharmacokinetic parameters were derived from plasma concentration-time data using noncompartmental methods.

resultsOf the 45 participants randomized, 37 completed the study. When activated charcoal was administered 2 h after mavacamten dosing, mavacamten absorption and exposure were reduced compared with when mavacamten was administered alone: the area under the concentration-time curve from 0 to 72 h (AUC

conclusionsActivated charcoal was successful in reducing mavacamten absorption and exposure when administered as soon as possible after identification of a need for adsorption (2 h after mavacamten dosing). No change in exposure was observed when activated charcoal was administered 6 h after mavacamten dosing. CLINICAL

trial registrationNCT05320094.

Indexed as

Area Under CurveCharcoalHealthy VolunteersAdultDrug InteractionsFemaleHumansMaleMiddle AgedYoung AdultCharcoal

Identifiers

PMID38926266
PMCPMC11233281

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.